Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call Transcript
Key Points
- Ultragenyx Pharmaceutical Inc (RARE) reported a 28% revenue growth in Q1 2025 compared to Q1 2024, driven by strong performance across its product portfolio.
- The company has made significant progress in its late-stage clinical programs, including UX143 for osteogenesis imperfecta and GTX102 for Angelman syndrome, with promising data expected in 2026.
- Ultragenyx is actively expanding its global footprint, with successful commercialization efforts for Crysvita in Latin America and Evkeeza in Europe and Japan.
- The company is on track to submit two BLAs in 2025, with UX111 for Sanfilippo syndrome under FDA review and DTX401 for GSDIa expected to be submitted mid-year.
- Ultragenyx has a strong cash position with $563 million in cash, cash equivalents, and marketable securities, providing financial stability for ongoing and future projects.
- Ultragenyx reported a net loss of $151 million for Q1 2025, highlighting ongoing financial challenges despite revenue growth.
- The company faces variability in revenue due to uneven ordering patterns for Crysvita in Latin America, which could impact financial predictability.
- There are uncertainties related to regulatory approvals and potential delays in clinical trial readouts, which could affect the timeline for product launches.
- Operating expenses remain high at $282 million for the quarter, driven by significant R&D and SG&A costs, which could pressure profitability.
- The company is navigating complex pricing negotiations and reimbursement challenges in various international markets, which could impact revenue growth.
Good afternoon, and welcome to the Ultragenyx first-quarter 2025 financial results conference call. (Operator Instructions)
Now my pleasure to turn the call over to Joshua Higa, Vice President of Investor Relations.
Thank you. We've issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer, and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call will be making forward-looking statements. These statements are subject to certain risks and uncertainties. Our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call over to Emil.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
